SIN - Italian Society of Nephrology
banner
sinnefro.bsky.social
SIN - Italian Society of Nephrology
@sinnefro.bsky.social
Official account of Italian Society of Nephrology - Account ufficiale della Società Italiana di Nefrologia (SIN)
Reposted by SIN - Italian Society of Nephrology
@kireports.bsky.social November issue is out!

Read the latest news in research, highlights from current literature, comprehensive reviews, and in-depth case studies.

www.kireports.org/cu...

#ThisIsISN #Nephrology #Journal #Research #KidneyCommunity #Kidney #OpenAccess
November 6, 2025 at 6:00 AM
Reposted by SIN - Italian Society of Nephrology
The November 2025 issue is available now! Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:

bit.ly/3X1XpZj
October 30, 2025 at 10:00 AM
Reposted by SIN - Italian Society of Nephrology
The recording of our joint webinar with @theisn.org: "What's New in Patient Training", focused on the recently published Position Paper on Teaching #PeritonealDialysis to Patients and Caregivers, is already available on our Youtube channel:
buff.ly/P2N0NGV
What's New in PD Patient Training? - recorded webinar
youtu.be
October 24, 2025 at 6:45 AM
Reposted by SIN - Italian Society of Nephrology
The opening plenary at #KidneyWk looks phenomenal

Renal RCT Renaissance is upon us

(LBCT list drops tomorrow)

www.asn-online.org/education/ki...
October 16, 2025 at 1:10 PM
Reposted by SIN - Italian Society of Nephrology
Core Curriculum by Craig E. Gordon et al:

Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)
October 3, 2025 at 10:00 PM
Reposted by SIN - Italian Society of Nephrology
Excellent thread below

I will also plug this talk by Paola Romagnani on podocytopathies

youtu.be/bRMeqaGgA9I?...

#GlomCon #NephGR
September 24, 2025 at 12:00 AM
Reposted by SIN - Italian Society of Nephrology
𝗧𝗢𝗗𝗔𝗬: ISN Webinar: "Optimizing RAASi Therapy in Clinical Practice: A Case-Based Discussion."

🗓️ September 17
🕓 4 pm CEST
🔗 Free registration: http://lite.spr.ly/6...

This webinar is supported by @astra-zeneca.bsky.social and CSL Vifor
September 17, 2025 at 6:00 AM
Reposted by SIN - Italian Society of Nephrology
📣 Registration for #ISNWCN 2026 is open. This is your chance to be part of the leading global congress on kidney care!
✔️ Register early with exclusive discounted rates
✔️Apply for a travel grant
We can’t wait to welcome you in Yokohama! Secure your spot today ➡️http://lite.spr.ly/6...
September 17, 2025 at 8:50 AM
Reposted by SIN - Italian Society of Nephrology
Horisberger et al separate Lupus nephritis patients in 3 groups by blood:
healthy-like, interferon-dominant and CD8 T cell-dominant.
The CD8 T cell-dominant group had the highest biopsy activity score and highest response rate after 1 year; the healthy-like the most chronic damage. 🧪 ⑂ #NephSky
1/
September 6, 2025 at 5:16 PM
Reposted by SIN - Italian Society of Nephrology
Weekend Briefing for September 6, 2025:

New Images in Clinical Medicine: Acute Epididymo-orchitis in IgA Vasculitis nej.md/4m4UJV0

Five New Perspectives:

1️⃣ Caring for Patients with IDDs nej.md/47YdUfB
September 6, 2025 at 12:13 PM
Reposted by SIN - Italian Society of Nephrology
How common is kidney failure with MCD and FSGS?

More than we think … @brianrifkin.bsky.social breaks down the recent @asnpublications.bsky.social JASN paper from the RaDaR study www.nephjc.com/news/nephjc-...
September 5, 2025 at 8:30 PM
Reposted by SIN - Italian Society of Nephrology
New in #ASNJASN and at #Hypertension25: In a randomized, double-blind, placebo-controlled trial, Baxdrostat reduced systolic blood pressure in patients with CKD and uncontrolled hypertension. Read more about its safety and efficacy in patients with CKD here: kidney.pub/JASN0849
September 6, 2025 at 2:00 PM
Reposted by SIN - Italian Society of Nephrology
Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled #Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial ca. 2025 from @asnpublications.bsky.social @escardio.bsky.social
#Nephpearls #NephSky #ESCCongress

👉 journals.lww.com/jasn/fulltex...
September 6, 2025 at 3:13 PM
Reposted by SIN - Italian Society of Nephrology
@nephjc.bsky.social @lastwalsh.bsky.social just presented ACHIEVE results at #ANZSN. Here’s a some details of country differences not in the main paper
September 3, 2025 at 1:43 AM
Reposted by SIN - Italian Society of Nephrology
How do you treat challenging cases of antibody-mediated glomerular diseases? This #ASNCJASN article explains the options, their efficacy, and possible future directions for care. kidney.pub/CJASN0843
August 27, 2025 at 6:00 PM
Reposted by SIN - Italian Society of Nephrology
>7.000 kidney transplant recipients
on SGLT2 inhibitors & GLP-1RAs

▶️ better survival, cardiovascular & kidney outcomes, weight loss, lower HbA1c

no safety risks
tinyurl.com/4p6fdybn
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney... : Transplantation
ovascular and kidney benefits in non-KT recipients, but evidence in KT recipients remains limited. This systematic review and meta-analysis provide updated evidence on the efficacy and safety of SGLT2...
tinyurl.com
August 25, 2025 at 9:36 PM
Reposted by SIN - Italian Society of Nephrology
The ISN Rare Kidney Diseases Toolkit offers concise, expert-led guidance to support timely recognition and informed decision-making in complex cases. Check out our latest tool on ADPKD and explore even more resources in the toolkit.

http://lite.spr.ly/6...
August 25, 2025 at 12:00 PM
Reposted by SIN - Italian Society of Nephrology
It's finally here!!
#NephJC summer book club 📚
Everything is Tuberculosis by @johngreensbluesky.bsky.social
8/19/25 @ 9pm EST
Come for the discussion, stay for stories.
www.nephjc.com/news/2025/8/...
#NephJC Summer Bookclub: Everything is Tuberculosis by John Green — NephJC
The summer book club started in 2015 , with one of the best books we have done in book club, Atul Gawande's Being Mortal . I think it should be required reading for all physicians. So now, in 2025, ...
www.nephjc.com
August 18, 2025 at 2:40 PM
Reposted by SIN - Italian Society of Nephrology
#Quiz from January 2022:

A 57-year-old woman presented with severe hypokalemia; the electrocardiogram showed sinus arrhythmia, flattened T waves, and prolonged QT interval of 667ms.

How should this patient be treated?

bit.ly/3pFr8au (FREE)
July 26, 2025 at 10:00 AM
Reposted by SIN - Italian Society of Nephrology
Among 223 patients with scleroderma renal crisis, 24% were late-onset (>5 years), with mean onset 12 years after initial diagnosis of systemic sclerosis. Exposure to steroids was significantly associated with late-onset scleroderma renal crisis

AC&R
doi.org/10.1002/acr....

#Medsky #Nephsky
July 21, 2025 at 12:49 PM
Reposted by SIN - Italian Society of Nephrology
The Columbia Renal Biopsy Course 2025 starts tomorrow! Don’t forget to register using the following link: web.cvent.com/event/...
July 16, 2025 at 12:06 AM
Reposted by SIN - Italian Society of Nephrology
📝 Want your abstract to stand out?

Join our webinar on 5 Aug to sharpen your abstract writing – perfect for QI, qualitative, mixed-methods & clinical trials.

✅ Expert tips
✅ Q&A
✅Practical resources

📅 Save the date

📥Submit to #UKKW26 by 19 Sept!
www.ukkw.org/abstracts
July 15, 2025 at 10:58 AM
Reposted by SIN - Italian Society of Nephrology
In 15 patients with primary aldosteronism, baxdrostat (a second-generation, nonimidazole aldosterone synthase inhibitor) resolved or reduced the severity of hypertension, excessive aldosterone production, and hypokalemia. Full SPARK study results: nej.md/40Js1kz

#ENDO2025
July 13, 2025 at 10:06 PM